1 Market Overview of Tubulin Inhibitors for Breast Cancer 1.1 Tubulin Inhibitors for Breast Cancer Market Overview 1.1.1 Tubulin Inhibitors for Breast Cancer Product Scope 1.1.2 Tubulin Inhibitors for Breast Cancer Market Status and Outlook 1.2 Global Tubulin Inhibitors for Breast Cancer Market Size Overview by Region 2016 VS 2021VS 2027 1.3 Global Tubulin Inhibitors for Breast Cancer Market Size by Region (2016-2027) 1.4 Global Tubulin Inhibitors for Breast Cancer Historic Market Size by Region (2016-2021) 1.5 Global Tubulin Inhibitors for Breast Cancer Market Size Forecast by Region (2022-2027) 1.6 Key Regions, Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.1 North America Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.2 Europe Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.3 Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.4 Latin America Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.5 Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) 2 Tubulin Inhibitors for Breast Cancer Market Overview by Type 2.1 Global Tubulin Inhibitors for Breast Cancer Market Size by Type: 2016 VS 2021 VS 2027 2.2 Global Tubulin Inhibitors for Breast Cancer Historic Market Size by Type (2016-2021) 2.3 Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size by Type (2022-2027) 2.4 Eribulin 2.5 Ixabepilone 2.6 Docetaxel 2.7 Trastuzumab Emtansine 2.8 Utidelone 2.9 Paclitaxel 2.10 Liposome Paclitaxel 2.11 Protein-bound Paclitaxel 3 Tubulin Inhibitors for Breast Cancer Market Overview by Application 3.1 Global Tubulin Inhibitors for Breast Cancer Market Size by Application: 2016 VS 2021 VS 2027 3.2 Global Tubulin Inhibitors for Breast Cancer Historic Market Size by Application (2016-2021) 3.3 Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size by Application (2022-2027) 3.4 Hospital 3.5 Clinic 3.6 Drug Center 3.7 Other 4 Tubulin Inhibitors for Breast Cancer Competition Analysis by Players 4.1 Global Tubulin Inhibitors for Breast Cancer Market Size by Players (2016-2021) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Tubulin Inhibitors for Breast Cancer as of 2020) 4.3 Date of Key Players Enter into Tubulin Inhibitors for Breast Cancer Market 4.4 Global Top Players Tubulin Inhibitors for Breast Cancer Headquarters and Area Served 4.5 Key Players Tubulin Inhibitors for Breast Cancer Product Solution and Service 4.6 Competitive Status 4.6.1 Tubulin Inhibitors for Breast Cancer Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Eisai 5.1.1 Eisai Profile 5.1.2 Eisai Main Business 5.1.3 Eisai Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.1.4 Eisai Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.1.5 Eisai Recent Developments 5.2 Bristol-Myers Squibb 5.2.1 Bristol-Myers Squibb Profile 5.2.2 Bristol-Myers Squibb Main Business 5.2.3 Bristol-Myers Squibb Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.2.4 Bristol-Myers Squibb Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.2.5 Bristol-Myers Squibb Recent Developments 5.3 Otsuka Pharmaceutical 5.5.1 Otsuka Pharmaceutical Profile 5.3.2 Otsuka Pharmaceutical Main Business 5.3.3 Otsuka Pharmaceutical Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.3.4 Otsuka Pharmaceutical Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.3.5 Hengrui Medicine Recent Developments 5.4 Hengrui Medicine 5.4.1 Hengrui Medicine Profile 5.4.2 Hengrui Medicine Main Business 5.4.3 Hengrui Medicine Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.4.4 Hengrui Medicine Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.4.5 Hengrui Medicine Recent Developments 5.5 Sanofi 5.5.1 Sanofi Profile 5.5.2 Sanofi Main Business 5.5.3 Sanofi Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.5.4 Sanofi Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.5.5 Sanofi Recent Developments 5.6 Qilu Pharma 5.6.1 Qilu Pharma Profile 5.6.2 Qilu Pharma Main Business 5.6.3 Qilu Pharma Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.6.4 Qilu Pharma Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.6.5 Qilu Pharma Recent Developments 5.7 Shenzhen Main Luck Pharma 5.7.1 Shenzhen Main Luck Pharma Profile 5.7.2 Shenzhen Main Luck Pharma Main Business 5.7.3 Shenzhen Main Luck Pharma Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.7.4 Shenzhen Main Luck Pharma Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.7.5 Shenzhen Main Luck Pharma Recent Developments 5.8 Jiangsu Aosaikang Pharma 5.8.1 Jiangsu Aosaikang Pharma Profile 5.8.2 Jiangsu Aosaikang Pharma Main Business 5.8.3 Jiangsu Aosaikang Pharma Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.8.4 Jiangsu Aosaikang Pharma Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.8.5 Jiangsu Aosaikang Pharma Recent Developments 5.9 Genentech 5.9.1 Genentech Profile 5.9.2 Genentech Main Business 5.9.3 Genentech Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.9.4 Genentech Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.9.5 Genentech Recent Developments 5.10 Beijing Biostar Technologies 5.10.1 Beijing Biostar Technologies Profile 5.10.2 Beijing Biostar Technologies Main Business 5.10.3 Beijing Biostar Technologies Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.10.4 Beijing Biostar Technologies Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.10.5 Beijing Biostar Technologies Recent Developments 5.11 Celgene Corporation 5.11.1 Celgene Corporation Profile 5.11.2 Celgene Corporation Main Business 5.11.3 Celgene Corporation Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.11.4 Celgene Corporation Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.11.5 Celgene Corporation Recent Developments 5.12 Hospira 5.12.1 Hospira Profile 5.12.2 Hospira Main Business 5.12.3 Hospira Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.12.4 Hospira Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.12.5 Hospira Recent Developments 5.13 Biological E. 5.13.1 Biological E. Profile 5.13.2 Biological E. Main Business 5.13.3 Biological E. Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.13.4 Biological E. Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.13.5 Biological E. Recent Developments 5.14 Taj Accura 5.14.1 Taj Accura Profile 5.14.2 Taj Accura Main Business 5.14.3 Taj Accura Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.14.4 Taj Accura Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.14.5 Taj Accura Recent Developments 5.15 Khandelwal Laboratories 5.15.1 Khandelwal Laboratories Profile 5.15.2 Khandelwal Laboratories Main Business 5.15.3 Khandelwal Laboratories Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.15.4 Khandelwal Laboratories Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.15.5 Khandelwal Laboratories Recent Developments 5.16 Luye Pharma 5.16.1 Luye Pharma Profile 5.16.2 Luye Pharma Main Business 5.16.3 Luye Pharma Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.16.4 Luye Pharma Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.16.5 Luye Pharma Recent Developments 5.17 Beijing Youcare 5.17.1 Beijing Youcare Profile 5.17.2 Beijing Youcare Main Business 5.17.3 Beijing Youcare Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.17.4 Beijing Youcare Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.17.5 Beijing Youcare Recent Developments 5.18 Beijing Union 5.18.1 Beijing Union Profile 5.18.2 Beijing Union Main Business 5.18.3 Beijing Union Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.18.4 Beijing Union Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.18.5 Beijing Union Recent Developments 5.19 Haiyao 5.19.1 Haiyao Profile 5.19.2 Haiyao Main Business 5.19.3 Haiyao Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.19.4 Haiyao Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.19.5 Haiyao Recent Developments 5.20 Chuntch 5.20.1 Chuntch Profile 5.20.2 Chuntch Main Business 5.20.3 Chuntch Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.20.4 Chuntch Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.20.5 Chuntch Recent Developments 5.21 CSPC Pharmaceutical 5.21.1 CSPC Pharmaceutical Profile 5.21.2 CSPC Pharmaceutical Main Business 5.21.3 CSPC Pharmaceutical Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.21.4 CSPC Pharmaceutical Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.21.5 CSPC Pharmaceutical Recent Developments 5.22 Aosaikang Pharm 5.22.1 Aosaikang Pharm Profile 5.22.2 Aosaikang Pharm Main Business 5.22.3 Aosaikang Pharm Tubulin Inhibitors for Breast Cancer Products, Services and Solutions 5.22.4 Aosaikang Pharm Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.22.5 Aosaikang Pharm Recent Developments 6 North America 6.1 North America Tubulin Inhibitors for Breast Cancer Market Size by Country (2016-2027) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Tubulin Inhibitors for Breast Cancer Market Size by Country (2016-2027) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size by Region (2016-2027) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Tubulin Inhibitors for Breast Cancer Market Size by Country (2016-2027) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size by Country (2016-2027) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Tubulin Inhibitors for Breast Cancer Market Dynamics 11.1 Tubulin Inhibitors for Breast Cancer Industry Trends 11.2 Tubulin Inhibitors for Breast Cancer Market Drivers 11.3 Tubulin Inhibitors for Breast Cancer Market Challenges 11.4 Tubulin Inhibitors for Breast Cancer Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

List of Tables Table 1. Global Market Tubulin Inhibitors for Breast Cancer Market Size (US$ Million) Comparison by Region 2016 VS 2021 VS 2027 Table 2. Global Tubulin Inhibitors for Breast Cancer Market Size by Region (2016-2021) & (US$ Million) Table 3. Global Tubulin Inhibitors for Breast Cancer Market Size Share by Region (2016-2021) Table 4. Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size by Region (2022-2027) & (US$ Million) Table 5. Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size Share by Region (2022-2027) Table 6. Global Tubulin Inhibitors for Breast Cancer Market Size (US$ Million) by Type: 2016 VS 2021 VS 2027 Table 7. Global Tubulin Inhibitors for Breast Cancer Market Size by Type (2016-2021) & (US$ Million) Table 8. Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by Type (2016-2021) Table 9. Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size by Type (2022-2027) & (US$ Million) Table 10. Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by Type (2022-2027) Table 11. Global Tubulin Inhibitors for Breast Cancer Market Size (US$ Million) by Application: 2016 VS 2021 VS 2027 Table 12. Global Tubulin Inhibitors for Breast Cancer Market Size by Application (2016-2021) & (US$ Million) Table 13. Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by Application (2016-2021) Table 14. Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size by Application (2022-2027) & (US$ Million) Table 15. Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by Application (2022-2027) Table 16. Global Tubulin Inhibitors for Breast Cancer Revenue (US$ Million) by Players (2016-2021) Table 17. Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by Players (2016-2021) Table 18. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Tubulin Inhibitors for Breast Cancer as of 2020) Table 19. Date of Key Manufacturers Enter into Tubulin Inhibitors for Breast Cancer Market Table 20. Global Tubulin Inhibitors for Breast Cancer Top Players Headquarters and Area Served Table 21. Tubulin Inhibitors for Breast Cancer Product Solution and Service Table 22. Global Tubulin Inhibitors for Breast Cancer Players Market Concentration Ratio (CR5 and HHI) Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Eisai Basic Information List Table 25. Eisai Description and Business Overview Table 26. Eisai Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 27. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Eisai (2016-2021) Table 28. Eisai Recent Developments Table 29. Bristol-Myers Squibb Basic Information List Table 30. Bristol-Myers Squibb Description and Business Overview Table 31. Bristol-Myers Squibb Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 32. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Bristol-Myers Squibb (2016-2021) Table 33. Bristol-Myers Squibb Recent Developments Table 34. Otsuka Pharmaceutical Basic Information List Table 35. Otsuka Pharmaceutical Description and Business Overview Table 36. Otsuka Pharmaceutical Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 37. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Otsuka Pharmaceutical (2016-2021) Table 38. Otsuka Pharmaceutical Recent Developments Table 39. Hengrui Medicine Basic Information List Table 40. Hengrui Medicine Description and Business Overview Table 41. Hengrui Medicine Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 42. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Hengrui Medicine (2016-2021) Table 43. Hengrui Medicine Recent Developments Table 44. Sanofi Basic Information List Table 45. Sanofi Description and Business Overview Table 46. Sanofi Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 47. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Sanofi (2016-2021) Table 48. Sanofi Recent Developments Table 49. Qilu Pharma Basic Information List Table 50. Qilu Pharma Description and Business Overview Table 51. Qilu Pharma Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 52. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Qilu Pharma (2016-2021) Table 53. Qilu Pharma Recent Developments Table 54. Shenzhen Main Luck Pharma Basic Information List Table 55. Shenzhen Main Luck Pharma Description and Business Overview Table 56. Shenzhen Main Luck Pharma Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 57. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Shenzhen Main Luck Pharma (2016-2021) Table 58. Shenzhen Main Luck Pharma Recent Developments Table 59. Jiangsu Aosaikang Pharma Basic Information List Table 60. Jiangsu Aosaikang Pharma Description and Business Overview Table 61. Jiangsu Aosaikang Pharma Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 62. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Jiangsu Aosaikang Pharma (2016-2021) Table 63. Jiangsu Aosaikang Pharma Recent Developments Table 64. Genentech Basic Information List Table 65. Genentech Description and Business Overview Table 66. Genentech Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 67. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Genentech (2016-2021) Table 68. Genentech Recent Developments Table 69. Beijing Biostar Technologies Basic Information List Table 70. Beijing Biostar Technologies Description and Business Overview Table 71. Beijing Biostar Technologies Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 72. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Beijing Biostar Technologies (2016-2021) Table 73. Beijing Biostar Technologies Recent Developments Table 74. Celgene Corporation Basic Information List Table 75. Celgene Corporation Description and Business Overview Table 76. Celgene Corporation Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 77. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Celgene Corporation (2016-2021) Table 78. Celgene Corporation Recent Developments Table 79. Hospira Basic Information List Table 80. Hospira Description and Business Overview Table 81. Hospira Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 82. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Hospira (2016-2021) Table 83. Hospira Recent Developments Table 84. Biological E. Basic Information List Table 85. Biological E. Description and Business Overview Table 86. Biological E. Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 87. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Biological E. (2016-2021) Table 88. Biological E. Recent Developments Table 89. Taj Accura Basic Information List Table 90. Taj Accura Description and Business Overview Table 91. Taj Accura Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 92. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Taj Accura (2016-2021) Table 93. Taj Accura Recent Developments Table 94. Khandelwal Laboratories Basic Information List Table 95. Khandelwal Laboratories Description and Business Overview Table 96. Khandelwal Laboratories Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 97. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Khandelwal Laboratories (2016-2021) Table 98. Khandelwal Laboratories Recent Developments Table 99. Luye Pharma Basic Information List Table 100. Luye Pharma Description and Business Overview Table 101. Luye Pharma Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 102. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Luye Pharma (2016-2021) Table 103. Luye Pharma Recent Developments Table 104. Beijing Youcare Basic Information List Table 105. Beijing Youcare Description and Business Overview Table 106. Beijing Youcare Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 107. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Beijing Youcare (2016-2021) Table 108. Beijing Youcare Recent Developments Table 109. Beijing Union Basic Information List Table 110. Beijing Union Description and Business Overview Table 111. Beijing Union Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 112. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Beijing Union (2016-2021) Table 113. Beijing Union Recent Developments Table 114. Haiyao Basic Information List Table 115. Haiyao Description and Business Overview Table 116. Haiyao Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 117. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Haiyao (2016-2021) Table 118. Haiyao Recent Developments Table 119. Chuntch Basic Information List Table 120. Chuntch Description and Business Overview Table 121. Chuntch Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 122. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Chuntch (2016-2021) Table 123. Chuntch Recent Developments Table 124. CSPC Pharmaceutical Basic Information List Table 125. CSPC Pharmaceutical Description and Business Overview Table 126. CSPC Pharmaceutical Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 127. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of CSPC Pharmaceutical (2016-2021) Table 128. CSPC Pharmaceutical Recent Developments Table 129. Aosaikang Pharm Basic Information List Table 130. Aosaikang Pharm Description and Business Overview Table 131. Aosaikang Pharm Tubulin Inhibitors for Breast Cancer Products, Services and Solutions Table 132. Revenue (US$ Million) in Tubulin Inhibitors for Breast Cancer Business of Aosaikang Pharm (2016-2021) Table 133. Aosaikang Pharm Recent Developments Table 134. North America Tubulin Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 135. North America Tubulin Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 136. Europe Tubulin Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 137. Europe Tubulin Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 138. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size by Region (2016-2021) & (US$ Million) Table 139. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size by Region (2022-2027) & (US$ Million) Table 140. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Share by Region (2016-2021) Table 141. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Share by Region (2022-2027) Table 142. Latin America Tubulin Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 143. Latin America Tubulin Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 144. Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size by Players (2016-2021) & (US$ Million) Table 145. Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 146. Tubulin Inhibitors for Breast Cancer Market Trends Table 147. Tubulin Inhibitors for Breast Cancer Market Drivers Table 148. Tubulin Inhibitors for Breast Cancer Market Challenges Table 149. Tubulin Inhibitors for Breast Cancer Market Restraints Table 150. Research Programs/Design for This Report Table 151. Key Data Information from Secondary Sources Table 152. Key Data Information from Primary Sources List of Figures Figure 1. Global Tubulin Inhibitors for Breast Cancer Market Size Year-over-Year 2016-2027 & (US$ Million) Figure 2. Global Tubulin Inhibitors for Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 3. Global Tubulin Inhibitors for Breast Cancer Market Share by Regions: 2021 VS 2027 Figure 4. Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size Share by Region (2022-2027) Figure 5. North America Tubulin Inhibitors for Breast Cancer Market Size (US$ Million) Growth Rate (2016-2027) Figure 6. Europe Tubulin Inhibitors for Breast Cancer Market Size (US$ Million) and Growth Rate (2016-2027) Figure 7. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size (US$ Million) and Growth Rate (2016-2027) Figure 8. Latin America Tubulin Inhibitors for Breast Cancer Market Size (US$ Million) and Growth Rate (2016-2027) Figure 9. Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size (US$ Million) and Growth Rate (2016-2027) Figure 10. Global Tubulin Inhibitors for Breast Cancer Market Size Share by Type in 2021 & 2027 Figure 11. Eribulin Market Size (US$ Million) YoY Growth (2016-2027) Figure 12. Ixabepilone Market Size (US$ Million) YoY Growth (2016-2027) Figure 13. Docetaxel Market Size (US$ Million) YoY Growth (2016-2027) Figure 14. Trastuzumab Emtansine Market Size (US$ Million) YoY Growth (2016-2027) Figure 15. Utidelone Market Size (US$ Million) YoY Growth (2016-2027) Figure 16. Paclitaxel Market Size (US$ Million) YoY Growth (2016-2027) Figure 17. Global Tubulin Inhibitors for Breast Cancer Market Size Share by Application in 2021 & 2027 Figure 18. Hospital Market Size (US$ Million) YoY Growth (2016-2027) Figure 19. Clinic Market Size (US$ Million) YoY Growth (2016-2027) Figure 20. Drug Center Market Size (US$ Million) YoY Growth (2016-2027) Figure 21. Other Market Size (US$ Million) YoY Growth (2016-2027) Figure 22. Tubulin Inhibitors for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 23. Global Top 5 and Top 10 Players Tubulin Inhibitors for Breast Cancer Market Share in 2020 Figure 24. North America Tubulin Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 25. United States Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 26. Canada Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 27. Germany Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 28. France Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 29. U.K. Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 30. Italy Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 31. Russia Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 32. Nordic Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 33. Rest of Europe Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 34. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Share by Region (2016-2027) Figure 35. China Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 36. Japan Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 37. South Korea Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 38. Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 39. India Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 40. Australia Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 41. Rest of Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 42. Latin America Tubulin Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 43. Mexico Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 44. Brazil Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 45. Rest of Latin America Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 46. Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 47. Turkey Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 48. Saudi Arabia Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 49. UAE Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 50. Rest of Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 51. Bottom-up and Top-down Approaches for This Report Figure 52. Data Triangulation

Eisai Bristol-Myers Squibb Otsuka Pharmaceutical Hengrui Medicine Sanofi Qilu Pharma Shenzhen Main Luck Pharma Jiangsu Aosaikang Pharma Genentech Beijing Biostar Technologies Celgene Corporation Hospira Biological E. Taj Accura Khandelwal Laboratories Luye Pharma Beijing Youcare Beijing Union Haiyao Chuntch CSPC Pharmaceutical Aosaikang Pharm